A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II)
Obesity2013Vol. 21(5), pp. 935–943
Citations Over TimeTop 1% of 2013 papers
Caroline M. Apovian, Louis J. Aronne, Domenica Rubino, Christopher D. Still, Holly R. Wyatt, Colleen Burns, Dennis Kim, Eduardo Dunayevich, for the COR‐II Study Group
Abstract
NB represents a novel pharmacological approach to the treatment of obesity, and may become a valuable new therapeutic option.
Related Papers
- → Pharmacokinetics of Single‐ and Multiple‐Dose Bupropion in Elderly Patients with Depression(1995)73 cited
- → The preclinical development of Medisorb® Naltrexone, a once a month long-acting injection, for the treatment of alcohol dependence(2005)37 cited
- Comparison of bupropion alone and with haloperidol in schizo-affective disorder, depressed type.(1983)
- → Use of naltrexone in reducing self-injurious behavior: A single case analysis(1989)17 cited
- → Comparison of two Naltrexone Treatment Programs: Naltrexone Alone versus Naltrexone Plus Behavior Therapy(1976)17 cited